Guidance

NHS trusts: area prevalence for sickle cell and thalassaemia

These documents list sickle cell and thalassaemia high and low prevalence NHS Trusts in England and explain how prevalence is determined.

• From: Public Health England
• Published: 1 January 2012
• Last updated: 3 August 2017 — See all updates

Documents

NHS sickle cell and thalassaemia screening programme: combined list of high prevalence and low prevalence trusts

PDF, 93.7 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Definitions of high and low prevalence

Low prevalence trusts are those where less than 1% of the booking bloods received by the laboratory are screen positive. High prevalence trusts are those where this figure is greater than or equal to 2%. Trusts that are between these 2 cut-offs are considered borderline and should continue to use their current algorithm.

Low prevalence trusts

In low prevalence trusts, a family origin questionnaire (FOQ) is used. This assesses the risk of either the woman or the baby’s biological father being a carrier for sickle cell or other haemoglobin variants, or severe alpha thalassaemia. This identifies those who need testing for haemoglobin variants. The FOQ should be completed and sent to the laboratory with the sample.

High prevalence trusts

In high prevalence trusts all pregnant women are offered screening by a blood test for sickle cell and other haemoglobin variants. The FOQ should also be completed and sent to the laboratory with the sample. This helps laboratory staff to interpret the results and identify those at risk of severe alpha thalassaemia.

Trust mergers

The high prevalence algorithm is viewed as the gold standard. In the event of trust mergers, low prevalence trusts should move to the high prevalence algorithm rather than high prevalence trusts moving to the low prevalence algorithm.

There is no need to offer screening by a blood test for sickle cell and other haemoglobin variants again in the same pregnancy if a woman has already been screened in a low prevalence area but chooses to give birth in a maternity unit in a high prevalence area.

Each laboratory should run only one screening algorithm, either the high or low prevalence.

Further information

For more information on undertaking the screening test and the FOQ, please see the Sickle Cell and Thalassaemia Screening e-learning module on e-learning for Health.

For more information on the high and low prevalence testing algorithms, see the Sickle cell and thalassaemia screening: handbook for laboratories.

Published 1 January 2012
Last updated 3 August 2017 + show all updates

1. 3 August 2017

   Updated guidance for local screening providers.

2. 20 August 2015

   Updated document for accuracy

3. 1 January 2012

   First published.